About: Barrish Joel

Documentation

scienceplus.abes.fr version Bêta

scienceplus.abes.fr | explorer

À propos de : Barrish Joel Goto Sponge NotDistinct Permalink

Attributs	Valeurs
type	Person
name	Barrish Joel Barrish Joel C.
familyName	Barrish
Given name	Joel Joel C.
is relates of	http://hub.abes.fr/acs/periodical/jmcmar/1993/volume_36/issue_10/101021jm00062a013/authorship/7 http://hub.abes.fr/acs/periodical/jmcmar/2006/volume_49/issue_7/101021jm051106d/authorship/11 http://hub.abes.fr/acs/periodical/jmcmar/2002/volume_45/issue_11/101021jm0105777/authorship/22 http://hub.abes.fr/acs/periodical/jmcmar/2004/volume_47/issue_25/101021jm049521d/authorship/33 http://hub.abes.fr/acs/periodical/jmcmar/2008/volume_51/issue_9/101021jm800001n/authorship/30 http://hub.abes.fr/acs/periodical/bichaw/2004/volume_43/issue_34/101021bi049428r/authorship/24 http://hub.abes.fr/acs/periodical/jmcmar/2008/volume_51/issue_1/101021jm7009414/authorship/25 http://hub.abes.fr/acs/periodical/jmcmar/2002/volume_45/issue_23/101021jm020366h/authorship/23 http://hub.abes.fr/acs/periodical/jmcmar/2003/volume_46/issue_1/101021jm020289q/authorship/21 http://hub.abes.fr/acs/periodical/jmcmar/2006/volume_49/issue_13/101021jm060347y/authorship/3 http://hub.abes.fr/acs/periodical/jmcmar/2006/volume_49/issue_24/101021jm0610806/authorship/45 http://hub.abes.fr/acs/periodical/jmcmar/2000/volume_43/issue_16/101021jm000105c/authorship/15 http://hub.abes.fr/acs/periodical/jmcmar/2005/volume_48/issue_20/101021jm0503594/authorship/17 http://hub.abes.fr/acs/periodical/jmcmar/2002/volume_45/issue_18/101021jm020138n/authorship/19 http://hub.abes.fr/acs/periodical/jmcmar/2007/volume_50/issue_15/101021jm070299x/authorship/20 http://hub.abes.fr/acs/periodical/joceah/2003/volume_68/issue_26/101021jo035377c/authorship/7 http://hub.abes.fr/acs/periodical/jmcmar/2005/volume_48/issue_12/101021jm0501275/authorship/14 http://hub.abes.fr/acs/periodical/jmcmar/2008/volume_51/issue_6/101021jm7013309/authorship/19 http://hub.abes.fr/acs/periodical/jmcmar/2004/volume_47/issue_18/101021jm030217e/authorship/25 http://hub.abes.fr/acs/periodical/jmcmar/2006/volume_49/issue_23/101021jm060727j/authorship/21 http://hub.abes.fr/acs/periodical/jmcmar/2004/volume_47/issue_27/101021jm049486a/authorship/5 http://hub.abes.fr/acs/periodical/joceah/2004/volume_69/issue_3/101021jo0355348/authorship/6 http://hub.abes.fr/acs/periodical/joceah/1993/volume_58/issue_16/101021jo00068a059/authorship/1 http://hub.abes.fr/acs/periodical/jmcmar/1994/volume_37/issue_12/101021jm00038a005/authorship/1 http://hub.abes.fr/acs/periodical/joceah/1987/volume_52/issue_7/101021jo00383a046/authorship/1 http://hub.abes.fr/acs/periodical/joceah/1988/volume_53/issue_18/101021jo00253a021/authorship/1 http://hub.abes.fr/acs/periodical/jacsat/1983/volume_105/issue_8/101021ja00346a071/authorship/2
is Author of	Interphenylene 7-oxabicyclo[2.2.1]heptane oxazoles. Highly potent, selective, and long-acting thromboxane A2 receptor antagonists Cupric bromide mediated oxidation of 4-carboxyoxazolines to the corresponding oxazoles Amino Diol HIV Protease Inhibitors. 1. Design, Synthesis, and Preliminary SAR Acridone-Based Inhibitors of Inosine 5‘-Monophosphate Dehydrogenase: Discovery and SARLeading to the Identification of N-(2-(6-(4-Ethylpiperazin-1-yl)pyridin-3-yl)propan-2-yl)-2-fluoro-9-oxo-9,10-dihydroacridine-3-carboxamide (BMS-566419) Design, Synthesis, and Anti-inflammatory Properties of Orally Active 4-(Phenylamino)-pyrrolo[2,1-f][1,2,4]triazine p38α Mitogen-Activated Protein Kinase Inhibitors Nucleophilic Aromatic Substitution ofMethacrylamide Anion and Its Applicationto the Synthesis of the Anticancer DrugBicalutamide Discovery of N-(2-Chloro-6-methyl-phenyl)-2-(6-(4-(2-hydroxyethyl)-piperazin-1-yl)-2-methylpyrimidin-4-ylamino)thiazole-5-carboxamide(BMS-354825), a Dual Src/Abl KinaseInhibitor with Potent Antitumor Activityin Preclinical Assays 5-Cyanopyrimidine Derivatives as a Novel Class of Potent, Selective, and OrallyActive Inhibitors of p38α MAP Kinase Discovery ofN-[2-[2-[[3-Methoxy-4-(5-oxazolyl)phenyl]amino]-5-oxazolyl]phenyl]-N-methyl-4-morpholineacetamide as a Novel andPotent Inhibitor of InosineMonophosphate Dehydrogenase withExcellent in Vivo Activity Discovery of Brivanib Alaninate ((S)-((R)-1-(4-(4-Fluoro-2-methyl-1H-indol-5-yloxy)-5-methylpyrrolo[2,1-f][1,2,4]triazin-6-yloxy)propan-2-yl)2-aminopropanoate), A Novel Prodrug of Dual Vascular Endothelial Growth Factor Receptor-2 and Fibroblast Growth Factor Receptor-1 Kinase Inhibitor (BMS-540215) Discovery and Preclinical Studies of(R)-1-(4-(4-Fluoro-2-methyl-1H-indol-5-yloxy)-5-methylpyrrolo[2,1-f][1,2,4]triazin-6-yloxy)propan-2-ol (BMS-540215), an In Vivo Active PotentVEGFR-2 Inhibitor Discovery and Development of 5-[(5S,9R)-9-(4-Cyanophenyl)-3-(3,5-dichlorophenyl)-1-methyl-2,4-dioxo-1,3,7-triazaspiro[4.4]non-7-yl-methyl]-3-thiophenecarboxylic Acid(BMS-587101)A Small Molecule Antagonist ofLeukocyte Function Associated Antigen-1 Selective Itk Inhibitors Block T-Cell Activation and Murine Lung Inflammation The Discovery of Orally Active Triaminotriazine Aniline Amides as Inhibitorsof p38 MAP Kinase Design, Synthesis, and Evaluation of Orally Active4-(2,4-Difluoro-5-(methoxycarbamoyl)phenylamino)pyrrolo[2,1-f][1,2,4]triazinesas Dual Vascular Endothelial Growth Factor Receptor-2 and Fibroblast GrowthFactor Receptor-1 Inhibitors Discovery and Evaluation of N-Cyclopropyl-2,4-difluoro-5-((2-(pyridin-2-ylamino)thiazol-5-ylmethyl)amino)benzamide (BMS-605541), aSelective and Orally Efficacious Inhibitor ofVascular Endothelial Growth Factor Receptor-2 (3R,5S,E)-7-(4-(4-Fluorophenyl)-6-isopropyl-2-(methyl(1-methyl-1H-1,2,4-triazol-5-yl)amino)pyrimidin-5-yl)-3,5-dihydroxyhept-6-enoic Acid (BMS-644950): A Rationally Designed Orally Efficacious 3-Hydroxy-3-methylglutaryl Coenzyme-A Reductase Inhibitor with Reduced Myotoxicity Potential Biphenylsulfonamide Endothelin Receptor Antagonists. 2. Discovery of4‘-Oxazolyl Biphenylsulfonamides as a New Class of Potent, Highly SelectiveETA Antagonists Discovery of N-Isoxazolyl Biphenylsulfonamides as Potent Dual Angiotensin IIand Endothelin A Receptor Antagonists Discoveryof N-[2-[2-[[3-Methoxy-4-(5-oxazolyl)phenyl]amino]-5-oxazolyl]phenyl]-N-methyl-4-morpholineacetamide asa Novel and Potent Inhibitor of Inosine Monophosphate Dehydrogenase (IMPDH) with Excellent in VivoActivity. Biphenylsulfonamide Endothelin Receptor Antagonists. 4. Discovery ofN-[[2‘-[[(4,5-Dimethyl-3-isoxazolyl)amino]sulfonyl]-4-(2-oxazolyl)[1,1‘-biphenyl]-2-yl]methyl]-N,3,3-trimethylbutanamide (BMS-207940), A Highly Potent andOrally Active ETA Selective Antagonist Imidazoquinoxaline Src-Family Kinase p56Lck Inhibitors: SAR, QSAR, and theDiscovery of (S)-N-(2-Chloro-6-methylphenyl)-2-(3-methyl-1-piperazinyl)imidazo-[1,5-a]pyrido[3,2-e]pyrazin-6-amine (BMS-279700) as a Potent and Orally ActiveInhibitor with Excellent in Vivo Antiinflammatory Activity 2-Aminothiazole as a Novel Kinase Inhibitor Template. Structure−Activity Relationship Studiestoward the Discovery of N-(2-Chloro-6-methylphenyl)-2-[[6-[4-(2-hydroxyethyl)-1-piperazinyl)]-2-methyl-4-pyrimidinyl]amino)]-1,3-thiazole-5-carboxamide(Dasatinib, BMS-354825) as a Potent pan-Src Kinase Inhibitor A New Strategy for the Construction of theImidazo[1,5-a]quinoxalin-4-one RingSystem and Its Application to the EfficientSynthesis of BMS-238497, a Novel andPotent Lck Inhibitor A stereoselective synthesis of 1,3-diol derivatives and application to the ansa bridge of rifamycin S Total synthesis of pseudomonic acid C A new approach to the total synthesis of pseudomonic acid C

Alternative Linked Data Documents: ODE Content Formats:

RDF

ODATA

Microdata